https://www.selleckchem.com/pr....oducts/Cyclopamine.h
g, but further research is needed. The optimal antithrombotic treatment for patients with atrial fibrillation (AF) that undergo percutaneous coronary intervention (PCI) is controversial. Dual therapy (clopidogrel and a direct oral anticoagulant [DOAC]) is safer than triple therapy (warfarin, aspirin, and clopidogrel), while efficacy is unclear. We aimed to evaluate thrombin generation (TG) under dual and triple therapy. A noninterventional prospective trial in patients with AF undergoing PCI. Patients received 4 weeks of triple ther
Like
Comment
Share
